Phase III Multi-Institutional Trial of Adjuvant Chemotherapy With Paclitaxel, Estramustine, and Oral Etoposide Combined With Long-Term Androgen Suppression Therapy and Radiotherapy Versus Long-Term Androgen Suppression Plus Radiotherapy Alone for High-Risk Prostate Cancer: Preliminary Toxicity Analysis of RTOG 99-02

International Journal of Radiation Oncology Biology Physics

Volumn 73, Issue 3, 2009, Pages 672-678

  Rosenthal, Seth A ^a,b   Bae, Kyoungwha ^c   Pienta, Kenneth J ^d   Sobczak, Mark L ^e   Asbell, Sucha O ^f   Rajan, Raghu ^g   Kerlin, Kevin J ^h   Michalski, Jeff M ⁱ   Sandler, Howard M ^d  

^a Radiological Associates of Sacramento Medical Group Inc   (United States)

^b Sutter Cancer Center   (United States)

^c RADIATION THERAPY ONCOLOGY GROUP   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^f ALBERT EINSTEIN MEDICAL CENTER   (United States)

^g MCGILL UNIVERSITY   (Canada)

^h Wayne Radiation Oncology Center   (United States)

ⁱ WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Prostate cancer; Randomized clinical trials; Toxicity

Indexed keywords

ANTIGENS; CHEMOTHERAPY; ONCOLOGY; POLARIZATION; RADIOTHERAPY; RISK ANALYSIS; TUMORS;

ADJUVANT CHEMOTHERAPIES; ANDROGEN SUPPRESSIONS; ETOPOSIDE; FOUR CYCLES; GASTROINTESTINAL TOXICITIES; GENITOURINARY TOXICITIES; GLEASON SCORES; HEMATOLOGIC TOXICITIES; PACLITAXEL; PROSTATE CANCER; PROSTATE-SPECIFIC ANTIGENS; RADIATION THERAPY ONCOLOGY GROUPS; RANDOMIZED CLINICAL TRIALS; RANDOMIZED TRIALS;

TOXICITY;

ANTIANDROGEN; BICALUTAMIDE; ESTRAMUSTINE; ETOPOSIDE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ALLERGY; ANDROGEN SUPPRESSION THERAPY; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CARDIOTOXICITY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOCRINE DISEASE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HEARING DISORDER; HEART ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; INFECTION; INFECTION COMPLICATION; LIVER TOXICITY; LONG TERM CARE; LUNG DISEASE; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUTROPENIA; NEUTROPENIC INFECTION; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; REPRODUCTIVE TOXICITY; SEXUAL DYSFUNCTION; SINGLE DRUG DOSE; SKIN DISEASE; SKIN MANIFESTATION; STATISTICAL SIGNIFICANCE; THROMBOEMBOLISM; TREATMENT OUTCOME; UROGENITAL TRACT INFECTION; VISUAL DISORDER;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; ESTRAMUSTINE; ETOPOSIDE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PACLITAXEL; PROSTATIC NEOPLASMS; THROMBOEMBOLISM;

EID: 59849085489     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.05.020     Document Type: Article

References (18)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 17 (1999) 168-173
3. Pilepich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-Long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 (2005) 1285-1290
4. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337 (1997) 295-300
5. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial. Lancet 360 (2002) 103-106
6. Hanks G.E., Pajak T.F., Porter A., et al. A phase III trial of long term adjuvant androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The RTOG protocol 92-02. J Clin Oncol 21 (2003) 3972-3978
7. Horwitz E.M., Bae K., Hanks G.E., et al. Ten-year follow-up of a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer: RTOG 92-02. J Clin Oncol 26 (2008) 2497-2504
8. Smith D.C., Esper P., Strawderman M., et al. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 17 (1999) 1664-1671
9. Cox J.D., Stetz J., Pajak T.F., et al. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31 (1995) 1341-1346
10. Pienta K.J., Fisher E.I., Eisenberger M.A., et al. A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407). Prostate 46 (2001) 257-261
11. Smith D.C., Chay C.H., Dunn R.L., et al. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma. Cancer 98 (2003) 269-276
12. Meluch A.A., Greco F.A., Morrissey L.H., et al. Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma. Cancer 98 (2003) 2192-2198
13. Berry W.R., Hathorn J.W., Dakhil S.R., et al. Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer. Clin Prostate Cancer 3 (2004) 104-111
14. Fizazi K., Le Maitre A., Hudes G., et al. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: A meta-analysis of individual patient data. Lancet Oncol 8 (2007) 994-1000
15. Flaig T.W., Tangen C.M., Hussain M.H., et al. Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J Clin Oncol 26 (2008) 1532-1536
16. Tannock I.F., deWit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
17. Dearnaley D.P., Sydes M.R., Graham J.D., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RTO1 randomised controlled trial. Lancet Oncol 8 (2007) 475-487
18. Kuban D.A., Tucker S.L., Dong L., et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008) 67-74